The ADRIATIC study marks a major advancement in limited-stage small cell lung cancer (LS-SCLC), showing that consolidation therapy with durvalumab after chemoradiation significantly improves overall survival (OS) and progression-free survival (PFS). This establishes durvalumab as the new standard of care for LS-SCLC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.medj.2024.10.004 | DOI Listing |
Publication Analysis
Top Keywords
adriatic face
4
face adriatic
4
adriatic study
4
study marks
4
marks major
4
major advancement
4
advancement limited-stage
4
limited-stage small
4
small cell
4
cell lung
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!